{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:32:10Z","timestamp":1762101130631},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T00:00:00Z","timestamp":1287619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Pemphigus vulgaris is a rare life-threatening autoimmune bullous disease caused by immunoglobulin G (IgG) autoantibodies directed against desmogleins 1 and 3. Previously, we showed that intravenous immunoglobulin (IVIG) ameliorates anti-desmoglein-induced experimental pemphigus vulgaris in newborn naive mice. The aim of this study was to examine the efficacy of anti-anti-desmoglein-specific IVIG in a similar model. Pemphigus-vulgaris-specific IVIG (PV-sIVIG) was affinity-purified from IVIG on a column of single-chain variable fragment (scFv) anti-desmogleins 1 and 3. The anti-idiotypic activity of PV-sIVIG was confirmed by enzyme-linked immunosorbent assay, inhibition assay. After induction of pemphigus by injection of anti-desmogleins 1 and 3 scFv to newborn mice, the animals were treated with PV-sIVIG, IVIG (low or high dose) or IgG from a healthy donor (n = 10 each). The skin was examined 24\u201348 h later, and samples of affected areas were analysed by histology and immunofluorescence. In vitro study showed that PV-sIVIG significantly inhibited anti-desmogleins 1 and 3 scFv binding to recombinant desmoglein-3 in a dose-dependent manner. Specificity was confirmed by inhibition assay. In vivo analysis revealed cutaneous lesions of pemphigus vulgaris in mice injected with normal IgG (nine of 10 mice) or low-dose IVIG (nine of 10 mice), but not in mice treated with PV-sIVIG (none of 10) or high-dose IVIG (none of 10). On immunopathological study, PV-sIVIG and regular IVIG prevented the formation of acantholysis and deposition of IgG in intercellular spaces. In conclusion, the PV-sIVIG preparation is more effective than native IVIG in inhibiting anti-desmoglein-induced pemphigus vulgaris in mice and might serve as a future therapy in patients with the clinical disease.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2010.04265.x","type":"journal-article","created":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T11:20:24Z","timestamp":1287660024000},"page":"543-549","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris"],"prefix":"10.1093","volume":"162","author":[{"given":"D","family":"Mimouni","sequence":"first","affiliation":[{"name":"Department of Medicine B and Zabludowicz Center for Autoimmune Diseases"},{"name":"Department of Dermatology, Rabin Medical Center, Petah Tiqwa"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Blank","sequence":"additional","affiliation":[{"name":"Department of Medicine B and Zabludowicz Center for Autoimmune Diseases"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A S","family":"Payne","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J","family":"Anhalt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Avivi","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Sheba Medical Center, Tel Hashomer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Barshack","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Institute of Pathology, Sheba Medical Center, Tel Hashomer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"David","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rabin Medical Center, Petah Tiqwa"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Shoenfeld","sequence":"additional","affiliation":[{"name":"Department of Medicine B and Zabludowicz Center for Autoimmune Diseases"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,10,21]]},"reference":[{"key":"2021122708484165700_b1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198205203062001","article-title":"Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease","volume":"306","author":"Anhalt","year":"1982","journal-title":"N Engl J Med"},{"key":"2021122708484165700_b2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI117349","article-title":"Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus","volume":"94","author":"Amagai","year":"1994","journal-title":"J Clin Invest"},{"key":"2021122708484165700_b3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","article-title":"Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins","volume":"159","author":"Ishii","year":"1997","journal-title":"J Immunol"},{"key":"2021122708484165700_b4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1529-8019.2002.01545.x","article-title":"Pemphigus","volume":"15","author":"Mimouni","year":"2002","journal-title":"Dermatol Ther"},{"key":"2021122708484165700_b5","first-page":"654","article-title":"Pemphigus","volume-title":"Fitzpatrick's dermatology in general medicine","author":"Stanley","year":"1999","edition":"5th"},{"key":"2021122708484165700_b6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","article-title":"Role of natural antibodies in immune homeostasis: IVIg perspective","volume":"7","author":"Vani","year":"2008","journal-title":"Autoimmun Rev"},{"key":"2021122708484165700_b7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2008.04.012","article-title":"What is the content of the magic draft IVIg?","volume":"7","author":"Seite","year":"2008","journal-title":"Autoimmun Rev"},{"key":"2021122708484165700_b8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-3148.2002.00360.x","article-title":"In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations \u2013 a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases","volume":"12","author":"Krause","year":"2002","journal-title":"Transfus Med"},{"key":"2021122708484165700_b9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122708484165700_b10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet"},{"key":"2021122708484165700_b11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1023\/A:1023239904856","article-title":"Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice","volume":"18","author":"Krause","year":"1998","journal-title":"J Clin Immunol"},{"key":"2021122708484165700_b12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00918187","article-title":"Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin","volume":"11","author":"Evans","year":"1991","journal-title":"J Clin Immunopathol"},{"key":"2021122708484165700_b13","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.4049\/jimmunol.143.12.4104","article-title":"Antiidiotypes against autoantibodies in pooled normal human polyspecific IgG","volume":"143","author":"Rossi","year":"1989","journal-title":"J Immunol"},{"key":"2021122708484165700_b14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2249.1991.tb05631.x","article-title":"Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis","volume":"83","author":"Rossi","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2021122708484165700_b15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0896-8411(92)90153-H","article-title":"Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity","volume":"5","author":"Tandon","year":"1992","journal-title":"J Autoimmun"},{"key":"2021122708484165700_b16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/clin.1993.1064","article-title":"Spontaneous recovery from the Guillain\u2013Barr\u00e9 syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies","volume":"67","author":"Lundkvist","year":"1993","journal-title":"Clin Immunol Immunopathol"},{"key":"2021122708484165700_b17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/jaut.1994.1039","article-title":"Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use","volume":"7","author":"Caccavo","year":"1994","journal-title":"J Autoimmun"},{"key":"2021122708484165700_b18","first-page":"46","article-title":"In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins","volume":"42","author":"Mehta","year":"1996","journal-title":"J Postgrad Med"},{"key":"2021122708484165700_b19","first-page":"587","article-title":"Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype","volume":"14","author":"DeKeyser","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2021122708484165700_b20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0022-510X(96)00053-6","article-title":"Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies","volume":"139","author":"Yuki","year":"1996","journal-title":"J Neurol Sci"},{"key":"2021122708484165700_b21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:JOCI.0000019809.55787.ec","article-title":"IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients","volume":"24","author":"Shoenfeld","year":"2004","journal-title":"J Clin Immunol"},{"key":"2021122708484165700_b22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1191\/096120399678841007","article-title":"A study of 20 SLE patients with intravenous immunoglobulin \u2013 clinical and serological response","volume":"8","author":"Levy","year":"1999","journal-title":"Lupus"},{"key":"2021122708484165700_b23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/08820130009060871","article-title":"Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations","volume":"29","author":"Terryberry","year":"2000","journal-title":"Immunol Invest"},{"key":"2021122708484165700_b24","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1191\/096120301701549705","article-title":"Antiphospholipid antibody levels in intravenous immunoglobulin (IVIG) preparations","volume":"10","author":"Sherer","year":"2001","journal-title":"Lupus"},{"key":"2021122708484165700_b25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2249.1994.tb06573.x","article-title":"Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations","volume":"97","author":"Silvestris","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2021122708484165700_b26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/096120339300200607","article-title":"In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin","volume":"2","author":"Evans","year":"1993","journal-title":"Lupus"},{"key":"2021122708484165700_b27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2249.2005.02947.x","article-title":"Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris","volume":"142","author":"Mimouni","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"2021122708484165700_b28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2021122708484165700_b29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1172\/JCI24185","article-title":"Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display","volume":"115","author":"Payne","year":"2005","journal-title":"J Clin Invest"},{"key":"2021122708484165700_b30","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.jid.5700790","article-title":"Targeting pemphigus autoantibodies through their heavy-chain variable region genes","volume":"127","author":"Payne","year":"2007","journal-title":"J Invest Dermatol"},{"key":"2021122708484165700_b31","first-page":"14","article-title":"Preparation and purification of active fragments from mouse monoclonal antibodies","volume-title":"Handbook of experimental immunology","author":"Parham","year":"1994"},{"key":"2021122708484165700_b32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/1523-1747.ep12343081","article-title":"Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients","volume":"106","author":"Amagai","year":"1996","journal-title":"J Invest Dermatol"},{"key":"2021122708484165700_b33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2133.2002.04838.x","article-title":"Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3","volume":"147","author":"Cheng","year":"2002","journal-title":"Br J Dermatol"},{"key":"2021122708484165700_b34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1172\/JCI114426","article-title":"Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb\/c mice","volume":"85","author":"Rock","year":"1990","journal-title":"J Clin Invest"},{"key":"2021122708484165700_b35","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4049\/jimmunol.137.9.2835","article-title":"Defining the role of complement in experimental pemphigus vulgaris in mice","volume":"137","author":"Anhalt","year":"1986","journal-title":"J Immunol"},{"key":"2021122708484165700_b36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/1523-1747.ep12513454","article-title":"Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum","volume":"67","author":"Schiltz","year":"1976","journal-title":"J Invest Dermatol"},{"key":"2021122708484165700_b37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.157.1.259","article-title":"Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells","volume":"157","author":"Hashimoto","year":"1983","journal-title":"J Exp Med"},{"key":"2021122708484165700_b38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1083\/jcb.137.5.1091","article-title":"Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris","volume":"137","author":"Koch","year":"1997","journal-title":"J Cell Biol"},{"key":"2021122708484165700_b39","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.0022-202X.2004.22426.x","article-title":"IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a pemphigus mouse model","volume":"122","author":"Shimizu","year":"2004","journal-title":"J Invest Dermatol"},{"key":"2021122708484165700_b40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1523-1747.1999.00463.x","article-title":"Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells","volume":"112","author":"Aoyama","year":"1999","journal-title":"J Invest Dermatol"},{"key":"2021122708484165700_b41","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/labinvest.3780168","article-title":"Assembly pathway of desmoglein 3 to desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured keratinocytes, as revealed by time-lapsed labeling immunoelectron microscopy","volume":"80","author":"Sato","year":"2000","journal-title":"Lab Invest"},{"key":"2021122708484165700_b42","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1074\/jbc.M512447200","article-title":"Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies","volume":"281","author":"Calkins","year":"2006","journal-title":"J Biol Chem"},{"key":"2021122708484165700_b43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jdermsci.2005.09.001","article-title":"Pemphigus vulgaris-IgG reduces the desmoglein 3\/desmocollin 3 ratio on the cell surface in cultured keratinocytes as revealed by double-staining immunoelectron microscopy","volume":"40","author":"Shu","year":"2005","journal-title":"J Dermatol Sci"},{"key":"2021122708484165700_b44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1083\/jcb.131.3.745","article-title":"Continual assembly of half-desmosomal structures in the absence of cell contacts and their frustrated endocytosis: a coordinated Sisyphus cycle","volume":"131","author":"Demlehner","year":"1995","journal-title":"J Cell Biol"},{"key":"2021122708484165700_b45","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4","article-title":"A pathogenic autoantibody, pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes","volume":"29","author":"Aoyama","year":"1999","journal-title":"Eur J Immunol"},{"key":"2021122708484165700_b46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1083\/jcb.153.4.823","article-title":"A central role for the armadillo protein plakoglobin in the autoimmune disease pemphigus vulgaris","volume":"153","author":"Caldelari","year":"2001","journal-title":"J Cell Biol"},{"key":"2021122708484165700_b47","doi-asserted-by":"crossref","first-page":"23778","DOI":"10.1074\/jbc.M501365200","article-title":"Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization","volume":"280","author":"Berkowitz","year":"2005","journal-title":"J Biol Chem"},{"key":"2021122708484165700_b48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2133.2004.06147.x","article-title":"In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades","volume":"151","author":"S\u00e1nchez-Carpintero","year":"2004","journal-title":"Br J Dermatol"},{"key":"2021122708484165700_b49","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archderm.138.9.1158","article-title":"Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris","volume":"138","author":"Sami","year":"2002","journal-title":"Arch Dermatol"},{"key":"2021122708484165700_b50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1067\/mjd.2002.122735","article-title":"Treatment of pemphigus with intravenous immunoglobulin","volume":"47","author":"Bystryn","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2021122708484165700_b51","first-page":"377","article-title":"Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris","volume":"13","author":"Sami","year":"2003","journal-title":"Eur J Dermatol"},{"key":"2021122708484165700_b52","first-page":"48","article-title":"Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins","volume":"84","author":"Herzog","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"2021122708484165700_b53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nm0104-17","article-title":"The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies","volume":"10","author":"Shoenfeld","year":"2004","journal-title":"Nat Med"},{"key":"2021122708484165700_b54","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/intimm\/dxm052","article-title":"The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model","volume":"19","author":"Blank","year":"2007","journal-title":"Int Immunol"},{"key":"2021122708484165700_b55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1385\/CRIAI:29:3:213","article-title":"Toward molecular targeting with specific intravenous immunoglobulin preparation","volume":"29","author":"Blank","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021122708484165700_b56","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","article-title":"Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus","volume":"14","author":"Shoenfeld","year":"2002","journal-title":"Int Immunol"},{"key":"2021122708484165700_b57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.11.020","article-title":"A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis","volume":"194","author":"Fuchs","year":"2008","journal-title":"J Neuroimmunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2010.04265.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/162\/3\/543\/41924402\/j.1365-2249.2010.04265.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/162\/3\/543\/41924402\/j.1365-2249.2010.04265.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T22:54:30Z","timestamp":1685832870000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/162\/3\/543\/6438619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,21]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,10,21]]},"published-print":{"date-parts":[[2010,11,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04265.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2010,12]]},"published":{"date-parts":[[2010,10,21]]}}}